



November 8, 2018

To: Jill Abrams, Esq., Vermont Assistant Attorney General

Via: Electronic Mail ([AGO.DrugCosts@vermont.gov](mailto:AGO.DrugCosts@vermont.gov); [AGO.highcostprescriptiondrugs@vermont.gov](mailto:AGO.highcostprescriptiondrugs@vermont.gov))

Re: Notice of new product introduction

Dear Madam:

Teva Pharmaceuticals USA, Inc. ("Teva") hereby provides a product introduction notice for Granix Vials. The Granix vials were commercially available on Wednesday, November 7, 2018.

NDC #	Product	WAC	Effective Date
63459-0918-59	Granix Vials 300 mcg (10-pack)	\$2,498.63	11/7/2018
63459-0920-59	Granix Vials 480 mcg (10-pack)	\$3,998.85	11/7/2018

Teva provides this notice consistent with its understanding and interpretation of Vermont Act 165 (18 V.S.A. § 4637) and its provisions. In providing this notice, Teva does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of Vermont Act 165 (18 V.S.A. § 4637) as it may relate to Teva or any of its affiliates now or in the future. Teva, on behalf of itself and affiliates, expressly reserves all such rights.

Sincerely,

Katie Hiett  
SVP, Strategic Pricing, Contracting & Customer Operations  
Teva Pharmaceuticals USA, Inc.